MedTrace Logo

Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers

NCT01723241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-01-12

No results posted yet for this study

Summary

This is a study to assess the safety, tolerability, and pharmacokinetics of XAF5 Gel when applied to the skin of healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

XAF5, concentration A

DRUG

XAF5, concentration B

DRUG

XAF5, concentration C

DRUG

Placebo

Sponsors & Collaborators

  • Topokine Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael S. Singer, MD, PhD · Topokine Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-04-30
Completion
2013-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723241 on ClinicalTrials.gov